
|Articles|July 21, 2008
NovaBay anounces details of dermatology program
Emeryville, Calif. - NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.
Advertisement
Emeryville, Calif.
- NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology, according to iStockAnalysis.com.
One formulations, AgaDerm, delivers an Aganocide compound effectively when applied on the surface of the skin, and furthered penetration into hair follicles to treat fungal infections.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















